請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/41276
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蔡偉博(Wei-bor Tsai) | |
dc.contributor.author | Cindy Yi Chi Hsieh | en |
dc.contributor.author | 謝尹綺 | zh_TW |
dc.date.accessioned | 2021-06-15T00:15:06Z | - |
dc.date.available | 2016-08-17 | |
dc.date.copyright | 2011-08-17 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-08-15 | |
dc.identifier.citation | [1] Ratner BD, Bryant SJ. BIOMATERIALS: Where We Have Been and Where We are Going. Annual Review of Biomedical Engineering. 2004;6:41-75.
[2] Anderson JM, Miller KM. Biomaterial biocompatibility and the macrophage. BIomaterials. 1984;5:5-10. [3] Ikada Y. Surface Modification of Polymers for Medical Application. BIomaterials. 1994;15:725-36. [4] Tsukagoshi T, Kondo Y, Yoshino N. Preparation of Thin Polymer Films with Drug Release and Protein Adsoprtion Resistance. Colloids and Surface B: Biointerfaces. 2007;55:19-25. [5] Anderson JM, Rodriguez A, Chang D. Foriegn Body Reaction to Biomaterials. Seminars in Immunology. 2008;20:86-100. [6] Ratner B. Reducing Capsular Thickness and Enhancing Angiogenesis Around Implant Drug Release system. Journal of Controlled Release. 2002;78:211-8. [7] Gorbet MB, Sefton MVMV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. BIomaterials. 2004;25:5681-703. [8] Anderson JM. Mechanisms of Inflammation and Infection with Implanted Device. Cardiovasc Pathol. 1993;2:33S-41S. [9] Bridges A, Burns NS, Babensee J, Andrew LL, Garc A. Reduced acute inflamatory responses to microgel conformal coatings,' Biomaterials. 2008;29. [10] Redpath M, Marques CMG, Dibden C, Waddon A, Lalla R, MacNeil S. Ibuprofen and hydrogel-released ibuprofen in the reduction of inflammation-induced migration in melanoma cells. British Journal of Dermatology. 2009;161:25-33. [11] Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine & Growth Factor Reviews.13:323-40. [12] Luttikhuizen DT, Harmsen MC, Luyn MJAV. Cellular and Molecular Dynamics in the Foreign Body Reaction. Tissue Engineering. 2006;12:1955-70. [13] Jones KS. Effects of biomaterial-induced inflammation on fibrosis and rejection. Seminars in Immunology. 2008;20:130-6. [14] Tripathi P, Tripathi P, Kashyap L, Singh V. The role of nitric oxide in inflammatory reactions. FEMS Immunology & Medical Microbiology. 2007;51:443-52. [15] Moilanen E, Knowles TMR, Charles I, Kadoya Y, Al-Saffar N. Nitric Oxide Synthase is Expressed in Human Macrophage During Forign Body Inflammation. American Journal of Pathology. 1997;150:881-7. [16] Taniguchi I. Materials for Biomedical Application. Massacusetts Institute of Technology lecture. 2004. [17] Peppas N, Bures P, Leobandung W, Ichikawa H. Hydrogels in Pharmaceutical Formulation. Eur J Pharm Biopharm. 2000;50:27-46. [18] Kiristin M, DeFife E, Nakayma Y, Matsuda T, Anderson JM. Spatial Regulation and Surface Chemistry Control of Monocyte/ Macrophage Adhesion and Foreign Body Giant Cell Formation by Photochemically Micropatterned Surface. Journal of Biomedical Materials Reasearch. 1999;45:148-54. [19] Brodbeck W, Y, Matsuda T, Colton E, Ziats N, Anderson JM. Biomaterial Surface Chemistry Dictates Adherent Monocyte/Macrophage Cytokine Expression in vitro. Cytokine. 2002;18:311-9. [20] Hoffman A, A.S. Non-Fouling Surface Technologies. JOurnal of BIomaterials Science, Polymer Edition. 1999;10:1011-4. [21] Ostuni E, Chapman RG, Holmlin RE, Takayama S, Whitesides GM. A Survey of Structure−Property Relationships of Surfaces that Resist the Adsorption of Protein. Langmuir. 2001;17:5605-20. [22] Chapman RG, Ostuni E, Takayama S, Holmlin RE, Yan L, Whitesides GM. Surveying for Surfaces that Resist the Adsorption of Proteins. Journal of the American Chemical Society. 2000;122:8303-4. [23] Zhang Z, Zhang M, Chen S, Horbett TA, Ratner BD, Jiang S. Blood compatibility of surfaces with superlow protein adsorption. BIomaterials. 2008;29:4285-91. [24] Peppas N, Keys K, Torres-Lugo M, Lowman A. Poly(ehtylene glycol)-containing Hydrogels in Drug Delivery. Journal of Controlled Release. 1999;62:81-7. [25] Xiang Y. Preparation of a Novel pH-responsive Silver Nanoparticle/ poly(HEMA-PEGMA-MAA) Composite Hydrogel. European Polymer Journal. 2007;43:4178-87. [26] Kim J-H, Kim J-G, Kim D, Him Y. Preparation and Porperties of PEG Hydrogel from PEG Macromonomer with Sulfonate End Group. Journal of Applied Polymer Science. 2005;96:56-61. [27] Chang Y, Cheng T-Y, Shih Y-J, Lee K-R, Lai J-Y. Biofouling-resistance expanded poly(tetrafluoroethylene) membrane with a hydrogel-like layer of surface-immobilized poly(ethylene glycol) methacrylate for human plasma protein repulsions. Journal of Membrane Science. 2008;323:77-84. [28] Kim MK, Park IS, Park HD, Wee WR, Lee JH, Park KD, et al. Effect of poly(ethylene glycol) graft polymerization of poly(methyl methacrylate) on cell adhesion : In vitro and in vivo study. Journal of Cataract & Refractive Surgery. 2001;27:766-74. [29] Park EL, Ulreich JB, Scott KM, Ullrich NPF, Linehan JA, French MH, et al. EVALUATION OF POLYETHYLENE GLYCOL BASED HYDROGEL FOR TISSUE SEALING AFTER LAPAROSCOPIC PARTIAL NEPHRECTOMY IN A PORCINE MODEL. The Journal of urology. 2004;172:2446-550. [30] Wendel H, Hauser N, Briquret F, Ziemer G. Hemocompatibility of Medical Connectors with Biopassive or BIoactive Surface Coating. J Biomater Appl. 2002;17:5-17. [31] Weber N, Wendel H, Ziemer G. Hemocompatibility of Heparin-coated Surfaces and the Role of Selective Plasma Protein Adsorption. Biomaterials. 2002;23:429-39. [32] Gong F, Cheng X, Wang S, Zhao Y, Gao Y, Cai H. Heparin-immobilized Polymers as Non-inflammatory and Non-thrombogenic Coating Materials for Arsenic Trioxide Eluting Stents. Acta Biomaterial. 2010;6:534-46. [33] van Bilsen PHJ, Popa ER, Brouwer LA, Vincent J, Taylor CE, de Leij LFMH, et al. Ongoing foreign body reaction to subcutaneous implanted (heparin) modified Dacron in rats. Journal of Biomedical Materials Research Part A. 2004;68A:423-7. [34] Crossley GH, Brinker JA, Reynolds D, Spencer W, Johnson WB, Hurd H, et al. Steroid Elution Improves the Stimulation Threshold in an Active-Fixation Atrial Permanent Pacing Lead : A Randomized, Controlled Study. Circulation. 1995;92:2935-9. [35] Udipi K, Ornberg RL, Thurmond KB, Settle SL, Forster D, Riley D. Modification of inflammatory response to implanted biomedical materials in vivo by surface bound superoxide dismutase mimics. Journal of Biomedical Materials Research. 2000;51:549-60. [36] Norton LW, Koschwanez HE, Wisniewski NA, Klitzman B, Reichert WM. Vascular endothelial growth factor and dexamethasone release from nonfouling sensor coatings affect the foreign body response. Journal of Biomedical Materials Research Part A. 2007;81A:858-69. [37] Stenson WF, Mehta J, Spilberg I. Sulfasalazine inhibition of binding of N-formyl-methionyl-leucyl-phenylalanine (FMLP) to its receptor on human neutrophils. Biochemical Pharmacology. 1984;33:407-12. [38] Dahinden C, Fehr J. Receptor-directed inhibition of chemotactic factor-induced neutrophil hyperactivity by pyrazolon derivatives. Definition of a chemotactic peptide antagonist. The Journal of Clinical Investigation. 1980;66:884-91. [39] Neal TM, Vissers MCM, Winterbourn CC. Inhibition by nonsteroidal anti-inflammatory drugs of superoxide production and granule enzyme release by polymorphonuclear leukocytes stimulated with immune complexes or formyl-methionyl-leucyl-phenylalanine. Biochemical Pharmacology. 1987;36:2511-7. [40] Walker JR, Smith MJH, Ford-Hutchinson AW. Anti-inflammatory drugs, prostaglandins and leucocyte migration. Inflammation Research. 1976;6:602-6. [41] Kaplan HB, Edelson HS, Korchak HM. Effects of non-steroidal anti-inflammatory agents on human neutrophil functions in vitro and in vivo. Biochemical Pharmacology. 1984;33:371-8. [42] Smith RJ. The guinea pig neutrophil calcium-dependent lysosomal enzyme secretory process. Inhibition by nonsteroid anti-inflammatory agents. Biochemical Pharmacology. 1979;28:2739-46. [43] Finkelstein AE, Roisman FR, Walz DT. Effect of auranofin, a new antiarthritic agent, on immune complex-induced release of lysosomal enzymes from human leukocytes. Inflammation. 1977;2:143-50. [44] Smith RG. A touch of CLASs. American Review of Respiratory Disease. 1978;117:618-20. [45] Smith RJ, Iden SS. Pharmacological modulation of chemotactic factor-elicited release of granule-associated enzymes from human neutrophils. Effects of prostaglandins, nonsteroid anti-inflammatory agents and corticosteroids. Biochemical Pharmacology. 1980;29:2389-95. [46] Kühn SH, Gemperli MB, Beer FC. Effect of two gold compounds on human polymorphonuclear leukocyte lysosomal function and phagocytosis. Inflammation. 1985;9:39-44. [47] Perianin A, Torres M, Labro MT, Hakim J. The different inhibitory effects of phenylbutazone on soluble and particle stimulation of human neutrophil oxidative burst. Biochemical Pharmacology. 1983;32:2819-22. [48] Gay JC, Lukens JN, English DK. Differential inhibition of neutrophil superoxide generation by nonsteroidal antiinflammatory drugs. Inflammation. 1984;8:209-22. [49] Minta JO, Williams MD. Some nonsteroidal antiinflammatory drugs inhibit the generation of superoxide anions by activated polymorphs by blocking ligand-receptor interactions. Journal of Rheumatology. 1985;12:751-7. [50] Vanderhoek JY, Bailey JM. Activation of a 15-lipoxygenase/leukotriene pathway in human polymorphonuclear leukocytes by the anti-inflammatory agent ibuprofen. Journal of Biological Chemistry. 1984;259:6752-6. [51] Stenson WF, Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. The Journal of Clinical Investigation. 1982;69:494-7. [52] F. J, DR. B. Clinical pharmacokinetics of ketoprofen and its enantiomers. Clin Pharacokinet. 1990;19:197-217. [53] Hamidi M, Azadi M, Rafiel P. Hydrogel Nanoparticles in Drug Delivery. Advanced Drug Delivery Review. 2008;60:1638-49. [54] Kim S, Kim J-H, Jeon O, Kwon I, Park K. Engineered Polymers for Advanced Drug Delivery. European Journal of Pharmaceutics and Biopharmaceutics. 2009;71:420-30. [55] Ma X, Oyamada S, Gao F, Wu T, Robich MP, Wu H, et al. Paclitaxel/sirolimus Combination Caoted Drug-eluting Stent: In vitro and In vivo Drug Release Studies. Journal of Pharmaceutical and Biomedical Analysis. 2011;54:801-11. [56] Lin C-C, Metters A. Hydrogels in Controlled Release Formulation: Network Design and Mathematical Modeling. Advanced Drug Delivery Reviews. 2006;58:1379-408. [57] Deligkaris K, Tadele T, Olthuis W, Berg A. Hydrogel-based device for Biomedical application. Sensors and Acutuators B. 2010;147:765-74. [58] DiRamio J, Kisaalita W, Majetich G, Shimku J. Poly(ethylene glycol) Methacylate/ Dimethacylate Hydrogels for Control Release of Hydrophobic Drugs. Biotechnology Progress. 2005;21:1281-8. [59] Bouwstra J, Jungiger H. In: Inc. M, editor. Encyclopedia of Pharmaceutical Technology. New York1993. p. 441. [60] Hennink W, Nostrum C. Novel Crosslinking Methods to Design Hydrogel. Advanced Drug Delivery Review. 2002;54:13-36. [61] Hennink W, Jong S, Bos G, Veldhuis T, Nostrum C. Biodegradable Dextran Hydrogels Crosslinked by Stereocomplex Formation for the Controlled Release of Pharmaceutical Proteins. Int J Pharm. 2004;277:99-104. [62] Hoare T, Kohane D. Hydrogels in Drug Delivery: Progress and Challenges. Polymer. 2008;49:1993-2007. [63] Peppas NA, Keys KB, Torres-Lugo M, Lowman AM. Poly(ethylene glycol)-containing hydrogels in drug delivery. Journal of Controlled Release. 1999;62:81-7. [64] Bryant SJ, Anseth KS. Hydrogel properties influence ECM production by chondrocytes photoencapsulated in poly(ethylene glycol) hydrogels. Journal of Biomedical Materials Research. 2002;59:63-72. [65] Mann BK, Gobin AS, Tsai AT, Schmedlen RH, West JL. Smooth muscle cell growth in photopolymerized hydrogels with cell adhesive and proteolytically degradable domains: Synthetic ECM analogs for tissue engineering. BIomaterials. 2001;22:3045-51. [66] Bryant SJ, Anseth KS. Controlling the spatial distribution of ECM components in degradable PEG hydrogels for tissue engineering cartilage. Journal of Biomedical Materials Research Part A. 2003;64A:70-9. [67] Sawhney AS, Pathak CP, Van Rensburg JJ, Dunn RC, Hubbell JA. Optimization of photopolymerized bioerodible hydrogel properties for adhesion prevention. Journal of Biomedical Materials Research. 1994;28:831-8. [68] Chowdhury SM, Hubbell JA. Adhesion prevention with ancrod released via a tissue-adherent hydrogel. Journal of Surgical Research. 1996;61:58-64. [69] Hermanson GT. Bioconjugate Techniques. San Diego: Academic Press.; 1996. [70] Sun Y, Takaba K, Kido H, Nakashima MN, Nakashima K. Simultaneous Determination of Arylpropionic Acidic Non-sterioidal Anti-inflammatory Drugs in Pharmaceutical Formulations and Human Plasma by HPLC with UV Detection. Journal of Pharmaceutical and Biomedical Analysis. 2003;30:1611-9. [71] Ricci M, Blasi P, Giovagnoli S, Rossi C, Macchiarulo G, Luca G, et al. Ketoprofen controlled release from composite microcapsules for cell encapsulation: Effect on post-transplant acute inflammation. Journal of Controlled Release. 2005;107:395-407. [72] Website. http://strain.bcrc.firdi.org.tw/BSAS/controller?event=SEARCH&bcrc_no=60001. Bioresource Collection and Research Center; 2004. [73] Website. www.promega.com. 2800 Woods Hollow Road USA: Promega Corporation. [74] Tang Q, Sun X, Li Q, Wu J, Lin J. Synthesis of polyacrylate/polyethylene glycol interpenetrating network hydrogel and its sorption of heavy-metal ions Science and Technology of Advanced Materials. 2009;10. [75] Petty HR. Regulation of RAW264 macrophage morphology and spreading: studies with protein kinase C activators, inhibitors and a cyclic AMP analog. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1989;1012:284-90. [76] Desai NP, Hubbell JA. Solution technique to incorporate polyethylene oxide and other water-soluble polymers into surfaces of polymeric biomaterials. BIomaterials. 1991;12:144-53. [77] Bartil T, Bounekhel M, Cedric C, Jerome R. Swelling Behavior and Release Properties of pH-sensitive Hydrogels-based on Methacrylic Derivatives. Acta Pharm 2007;57:301-14. [78] Kim B, Peppas NA. Poly(ethylene glycol)-containing Hydrogels for Oral Protein Delivery Applications. Biomedical Microdevices. 2003;5:333-41. [79] Zhou X, Weng L, Chen Q, Zhang J, Shen D, Li Z, et al. Investigation of pH sensitivity of poly(acrylic acid-co-acrylamide) hydrogel. Polymer International. 2003;52:1153-7. [80] Elliott JE, Macdonald M, Nie J, Bowman CN. Structure and swelling of poly(acrylic acid) hydrogels: effect of pH, ionic strength, and dilution on the crosslinked polymer structure. Polymer. 2004;45:1503-10. [81] Shi L, Yang L, Chen J, Pei Y, Chen M, Hui B, et al. Preparation and characterization of pH-sensitive hydrogel of chitosan/poly(acrylic acid) co-polymer. JOurnal of BIomaterials Science, Polymer Edition. 2004;15:465-74. [82] Jin X, Hsieh Y-L. pH-responsive swelling behavior of poly(vinyl alcohol)/poly(acrylic acid) bi-component fibrous hydrogel membranes. Polymer. 2005;46:5149-60. [83] Nicholson TE, Dibb S, Renton KW. Nitric oxide mediates an LPS-induced depression of cytochrome P450 (CYP1A) activity in astrocytes. Brain Research. 2004;1029:148-54. [84] Saxena RK, Vallyathan V, Lewis DM. Evidence for Lipopolysaccharideinduced Differentiation of RAW264.7 Marine Macrophage Cell line into Dendritic like Cells. Journal of Biosciences. 2003;28:129-34. [85] Chang C-Y, Tucci M, Baker RC. Lipopolysaccharide-stimulated nitric oxide production and inhibition of cell proliferation is antagonized by ethanol in a clonal macrophage cell line. Alcohol. 2000;20:37-43. [86] Larsson R, Selén G, Björklund H, Fagerholm P. Intraocular PMMA lenses modified with surface-immobilized heparin: evaluation of biocompatibility in vitro and in vivo. BIomaterials. 1989;10:511-6. [87] Nguyen KT, West JL. Photopolymerizable hydrogels for tissue engineering applications. BIomaterials. 2002;23:4307-14. [88] Pan C-J, Tang J-J, Weng Y-J, Wang J, Huang N. Prepartion and in vitro release profiles of drug-eluting controlled biodegradable polymer coating stents. Colloids and Surface B: Biointerfaces. 2009;73:199-206. [89] Corrigan OI, Li X. Quantifying Drug Release from PLGA Nanoparticulates. European Journal of Pharmaceutical Sciences. 2009;37:447-85. [90] Song X, Zhao Y, Hou S, Xu F, Zhao R, He J, et al. Dual Agents Loaded PLGA Nanoparticles: Systematic Study of Particle Size and Drug Entrapment Effciency. European Journal of Pharmaceutics and Biopharmaceutics. 2008;69:445-53. [91] Berkland C, King M, Cox A, Kim K, Pack DW. Precise Control of PLG Microsphere Size Provides Enhanced Control of Drug Release Rate. Journal of Controlled Release. 2002;82:137-47. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/41276 | - |
dc.description.abstract | 在生醫材料植入體內中,最常見的問題就是身體無法成功的自我修復。此狀況在長時間下會導致異物反應,並且驅使夾囊包覆的形成。在這個研究中,主要是以高分子塗佈的方式改質生醫材料表面,並利用其表面包覆抗發炎藥物來降低體外實驗巨蝕細胞的啟動及貼覆,跟體內實驗夾囊包覆的形成。在研究的第一個階段,我們成功利用一種光交聯親水高分子p(PEGMA-co-AA)-g-Az改質於聚甲基丙烯酸甲酯的表面,並且在細胞實驗中觀察到此改質方法能夠降低RAW264.7巨噬细胞的貼附及活化。另外,當探討改變塗布時的pH值及PEGMA與acrylic acid的聚合比例對巨噬细胞的影響時,可看出在pH 6.5下,PEGMA: Acrylic Acid等於9:1條件下可得到較低的細胞貼附及夾囊包覆。在第二階段的研究中,我們使用前述的條件來包覆含有30%抗發炎藥物酮基布洛芬(Ketoprofen)的聚乳酸聚甘醇酸(PLGA)微粒子,同樣進行上述細胞貼附與夾囊包覆之實驗。在實驗中我們發現此藥物成功的被包埋且能夠緩慢釋放,雖然研究中顯示巨噬细胞的貼附並沒有因為包覆藥物而有明顯差異,但在體內植入實驗卻有效的降低夾囊包覆的形成。 | zh_TW |
dc.description.abstract | Failure in turning on normal healing process has always been one of the major obstacles and complications in long-term artificial implants surgery. This can lead to possible foreign body reaction (FBR), where the implants may be encapsulated by fibrous collagen layer. In order to reduce host response, a facile polymer coating method was utilized in this study in reducing host response and foreign body reaction. In part 1 of this study, PMMA samples modified with p(PEGMA-co-AA)-g-Az copolymer successfully lowers RAW 264.7 cell adhesion and activation, with coating pH value of 6.5 and ratio of 9:1 PEGMA to acrylic acid copolymerization condition to exhibit lower macrophage adhesion. In vivo study also showed 13-15% reduction in encapsulation thickness with p(PEGMA-co-AA)-g-Az modified samples in compared to PMMA control. In part 2 of this study, the hydrogel successfully entrapped 30% (v/v) ketoprofen-PLGA micro-particles with low and sustained local release of anti-inflammatory drug. Though no difference in cell adhesion was observed with presence of ketoprofen, further in vivo analysis showed statistically lower encapsulated thickness with presence of ketoprofen in compared to p(PEGMA-co-AA)-g-Az without ketoprofen and PMMA control. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T00:15:06Z (GMT). No. of bitstreams: 1 ntu-100-R97524087-1.pdf: 2846739 bytes, checksum: dfa5a19017bc912153727bc3da225c10 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | Content
Abstract………………………………………………………………ii List of Tables………………………………………………………vi List of Figures……………………………………………………vii Chapter 1: Introduction……………………………………………1 1.1 Introduction…………………………………………………………1 1.1.1 Biomedical device………………………………………1 1.1.2 Biological and host response………………………………………………………………2 1.1.3 Inflammation and foreign body reaction…………3 1.1.4 Participation of cytokines in foreign body reaction………………………………………………………………5 1.1.5 Macrophage, foreign body giant cells, nitric oxide and their roles in foreign body reaction……………5 1.2 Common strategies of surface modification in reducing host response……………………………………………9 1.2.1 Common strategies for surface modification……9 1.2.2 Non-fouling and hydrophilic surface………………10 1.2.3 Non-specific protein adsorption resistant surface …………………………………………………………………………11 1.2.4 Poly(ethylene glycol),PEG……………………………13 1.2.5 Immobilization of heparin……………………………17 1.2.6 Controlled drug release device……………………18 1.3 Hydrogels…………………………………………………21 1.3.1 The significance of hydrogel………………………21 1.3.2 Classification of Hydrogels…………………………22 1.3.3 PEG-based hydrogel……………………………………24 1.4 Motive and Aims…………………………………………25 1.5 Research framework……………………………………26 Chapter 2: Materials and Methods………………………………29 2.1 Materials …………………………………………………29 2.1.1 Hydrogel fabrication…………………………………29 2.1.2 Drug-containing particles……………………………29 2.1.3 RAW 264.7 cell line culturing………………………30 2.1.4 Lactate dehydrogenase (LDH) assay…………………31 2.1.5 Nitric oxide (NO) assay: Griess reagent system…………………………………………………………………31 2.1.6 Hemotoxylin and Eosin section stainings…………32 2.2 Experimental equipments……………………………………32 2.2.1 Cell culture……………………………………………32 2.2.2 Drug & particle analysis……………………………33 2.2.3 Other equipments………………………………………33 2.3 Solution formulas………………………………………34 2.4 Methods……………………………………………………37 2.4.1 Synthesis of poly(PEGMA-co-AA)-g-Az hydrogel…37 2.4.2 Preparation of drug-loaded Poly(lactic-co-glycolic acid) (PLGA) particles 38 2.4.3 Preparation of PMMA film 39 2.4.4 Coating of hydrogel or particle-entrapping hydrogel………………………………………………………………39 2.4.5 Contact Angle analysis………………………………40 2.4.6 RAW 264.7 cell line culturing………………………41 2.4.7 Cell density analysis…………………………………42 2.4.8 NO releasing analysis…………………………………43 2.4.9 In vivo animal implantation…………………………44 2.4.10 Hemotoxylin & Eosin sections staining……………45 2.4.11 Drug loading, detachment and delivery analysis………………………………………………………………47 2.4.12 Statistic analysis ……………………………………48 Chapter 3: Application of p(PEGMA-co-AA)-g-Az Hydrogel for Resisting Foreign Body Reaction 49 3.1 Introduction 49 3.2 Surface and copolymer characterization 50 3.3 In vitro evaluation of RAW 264.7 cell line attachment & activation 52 3.4 In vivo evaluation by Hematoxylin & Eosin 55 3.5 Discussion 57 Chapter 4: Embedding of Ketoprofen-PLGA in p(PEGMA-co-AA)-g-Az Hydrogel for Resisting Foreign Body Reaction & Controlled Drug Release 78 4.1 Introduction 78 4.2 Surface and particle characterization 78 4.3 Drug loading and detachment 79 4.4 Drug release and kinetics 80 4.5 In vitro evaluation of RAW 264.7 cell line attachment 81 4.6 In vivo evaluation by Hematoxylin & Eosin staining 81 4.7 Discussion 82 Chapter 5: Conclusion 95 Appendix 1 97 Reference………………………………………………………………108 | |
dc.language.iso | zh-TW | |
dc.title | 生醫材料表面改質應用於降低宿主反應及藥物釋放 | zh_TW |
dc.title | Application of Surface Modification on Biomedical Device in Drug Delivery and Resistance to Host Response | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 戴子安(Chi-An Dai),陳文翔(Wenshiang Chen) | |
dc.subject.keyword | 生物相容性,聚乙二醇,巨噬细,胞,異物反應,藥物釋放, | zh_TW |
dc.subject.keyword | biocompatibility,poly(ethylene) glycol,macrophage,foreign body reaction,drug release, | en |
dc.relation.page | 107 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-08-15 | |
dc.contributor.author-college | 工學院 | zh_TW |
dc.contributor.author-dept | 化學工程學研究所 | zh_TW |
顯示於系所單位: | 化學工程學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 2.78 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。